Latest News Archive

Please select Category, Year, and then Month to display items
Years
2019 2020 2021 2024
Previous Archive
05 June 2019 | Story Leonie Bolleurs | Photo Leonie Bolleurs
Lucas Erasmus and Prof Hendrik Swart
Lucas Erasmus and Prof Hendrik Swart (right) are working on a joint project with Ghent University to find an attractive solution to address the energy demands of buildings, electric motor vehicles, and mobile electronics.

With a constant increase in the price of electricity, any innovation to replace this necessity in our daily lives is welcome. 

The University of the Free State (UFS), whose vision is supported by an element of innovation, welcomes the recent agreement between its Department of Physics and Ghent University.

Attractive solution


Not only will this research – which aims to develop the materials necessary for transparent solar panels – enlarge the international research footprint of the UFS, but it is also an attractive solution to address the energy demands of buildings, electric motor vehicles, and mobile electronics without affecting their appearance.

According to Prof Hendrik Swart, from the UFS Department of Physics, the agreement between the two universities entails a joint doctoral degree in which both universities will supervise the project and the awarding of the doctorate. The student, Lucas Erasmus, will conduct research at both institutions.

Transparent solar panel

The idea with the research is to develop glass that is transparent to visible light, just like the glass you find in the windows of buildings, motor vehicles, and mobile electronic devices. However, by incorporating the right phosphor materials inside the glass, the light from the sun that is invisible to the human eye (ultraviolet and infrared light) can be collected, converted, and concentrated to the sides of the glass panel where solar panels can be mounted. This invisible light can then be used to generate electricity to power these buildings, vehicles, and electronic devices. The invention is therefore a type of transparent solar panel.

Implemented in cellphone screens

This technology can be implemented in the building environment to meet the energy demands of the people inside the buildings. 

The technology is also good news for the 4,7 billion cellphone users in the world, as it can be implemented in the screens of cellphones, where the sun or the ambient light of a room can be used to power the device without affecting its appearance. 

Another possible application is in electric cars, where the windows can be used to help power the vehicle.

Low-income housing

Erasmus added: “We are also looking at implementing this idea into hard, durable plastics that can act as a replacement for zinc roofs.” 

“This will allow visible light to enter housing, and the invisible light can then be used to generate electricity. The device also concentrates the light from a large area to the small area on the sides where the solar panels are placed; therefore, reducing the number of solar panels needed and, in return, reducing the cost.”

The technology will take about a decade to implement.

“This study is currently ongoing, and we are experimenting and testing different materials in order to optimise the device in the laboratory. After this, it needs to be upscaled in order to test it in the field. It is truly the technology of the future,” said Erasmus.

Video: Barend Nagel

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept